Dr. Kaiser is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 800-223-2273
Education & Training
- Bascom Palmer Eye InstituteFellowship, 1996 - 1997
- Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
- Massachusetts Eye and Ear InfirmaryClinical, Ophthalmology, 1993 - 1996
- Massachusetts General HospitalInternship, Internal Medicine, 1992 - 1993
- Harvard Medical SchoolClass of 1992
- Harvard CollegeBachelor of Arts, 1984 - 1988
Certifications & Licensure
- FL State Medical License 2004 - 2026
- IL State Medical License 2002 - 2026
- MA State Medical License 2002 - 2026
- MI State Medical License 2002 - 2026
- OH State Medical License 1997 - 2026
- PA State Medical License 2002 - 2026
- CA State Medical License 2002 - 2025
- American Board of Ophthalmology Ophthalmology
- Join now to see all
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Lew R. Wasserman Merit Award Research to Prevent Blindness 2010
- American Academy of Ophthalmology Senior Achievement Award (Senior Honor Award) 2008
- Join now to see all
Clinical Trials
- Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy Start of enrollment: 2006 Jul 01
- Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD Start of enrollment: 2007 Jul 01
- Optical Coherence Tomography in Multiple Sclerosis Patients Start of enrollment: 2012 Aug 01
Publications & Presentations
PubMed
- 113 citationsCharacterization of the proteasome interaction network using a QTAX-based tag-team strategy and protein interaction network analysisCortnie Guerrero, Tijana Milenkovic, Natasa Przulj, Peter K. Kaiser, Lan Huang
Proceedings of the National Academy of Sciences of the United States of America. 2008-09-09 - 4030 citationsRanibizumab for Neovascular Age-Related Macular DegenerationPhilip J. Rosenfeld, David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser
The New England Journal of Medicine. 2006-10-05 - 296 citationsRANIBIZUMAB FOR PREDOMINANTLY CLASSIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: SUBGROUP ANALYSIS OF FIRST-YEAR ANCHOR RESULTSPeter K. Kaiser, David M. Brown, Kang Zhang, Henry L. Hudson, Frank G. Holz
American Journal of Ophthalmology. 2007-12-01
Journal Articles
- HIV-1 coat protein increases intracellular Ca2+ and injures neurons: toxicity prevented by calcium channel antagonists.Dreyer EB, Kaiser PK, Offermann JT, and Lipton SA., Science 1990
- Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies.Kaiser PK, Offermann JT, and Lipton SA., Neurology 1990
- VIP-mediated increase in cAMP prevents TTX-induced retinal ganglion cell death in vitro.Kaiser PK and Lipton SA., Neuron 1990
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A study of the effects of vasoactive intestinal peptide on natural cell death of retinal ganglion cells.Kaiser PK, Summa cum laude honors thesis; Harvard College
- Vasoactive intestinal peptide via cAMP rescues mammalian retinal ganglion cells from tetrodotoxin-induced death.Kaiser PK and Lipton SA, Society for Neuroscience
- Calcium channel antagonists partially prevent neuronal cell killing by HIV-1 coat protein gp120 in vitro.Campo R, Offermann JT, Arroyo JG, Kaiser PK, Chen HS V, and Lipton SA, Society for Neuroscience
- Join now to see all
Lectures
- New treatment strategies for corneal abrasions.New England Ophthalmological Society Meeting, Boston, MA
- Digital Journal of Ophthalmology and other world wide web resources for ophthalmologists.American Academy of Ophthalmology Annual Meeting
- Submacular Surgery Trials.Cleveland Ophthalmology Society Meeting
- Join now to see all
Press Mentions
- New Framework for Deciding When to Operate on Patients with Epiretinal MembranesNovember 11th, 2024
- Cimerli Approved as Interchangeable Biosimilar to LucentisAugust 3rd, 2022
- FDA Approves Coherus’ CIMERLI™ (Ranibizumab-Eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability ExclusivityAugust 2nd, 2022
- Join now to see all
Grant Support
- Vacsular Remodeling And Effects Of Angiogenic Inhibition In Diabetic RetinopathyNational Eye Institute2006
- Vascular Remodeling And Effects Of Angiogenic InhibitionNational Eye Institute2005
Professional Memberships
- Fellow
- Member
- Macula SocietyMember
- Retina SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: